Allarity wins Japanese patent for stenoparib DRP companion diagnostic; Japan protection runs to 2039

Allarity Therapeutics, Inc.

Japan Patent Office granted Japanese Patent No. 7917283 covering stenoparib-specific DRP companion diagnostic; Japan protection extends into 2039.
Patent covers DRP methods predicting clinical benefit from stenoparib via tumor gene-expression profiles and patient-selection methods.
Prior stenoparib DRP protection secured in US through April 2042, plus selected European jurisdictions and Australia; other filings pending.
CEO Thomas Jensen cites Japan as key pharma market and home of Eisai, original stenoparib developer, supporting drug's developability.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.